| Dr Michael Thomas Fabrizio, DO | |
|
8 Pinewood Ln, Cumberland, RI 02864-4225 | |
| (401) 333-2265 | |
| Not Available |
| Full Name | Dr Michael Thomas Fabrizio |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 51 Years |
| Location | 8 Pinewood Ln, Cumberland, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427021120 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 40813 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sturdy Memorial Hospital | Attleboro, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sturdy Memorial Associates Inc | 9537152806 | 177 |
News Archive
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced the Food and Drug Administration (FDA) has granted final approval for the BIOTRONIK Lumax 740 DX System.
According to an Australian Financial Review report the major pharmaceutical companies have agreed to reduce the Australian government's medicine bill by AUD $2 billion over the next four years only if they are assured of price modifications in future. The details of the agreement are to be revealed next week and experts believe it will reduce the burden on the federal budget which is still considering the source of funds to pay for its health reform package.
In the case of a cough or a sore throat, the doctor can usually diagnose a common cold immediately. However, the diagnosis of hereditary illnesses like cystic fibrosis, which affects the metabolism, or Huntington's disease, which leads to cognitive decline, is much more complex.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
› Verified 5 days ago
| Entity Name | Sturdy Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730106162 PECOS PAC ID: 4981653789 Enrollment ID: O20050119000678 |
News Archive
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced the Food and Drug Administration (FDA) has granted final approval for the BIOTRONIK Lumax 740 DX System.
According to an Australian Financial Review report the major pharmaceutical companies have agreed to reduce the Australian government's medicine bill by AUD $2 billion over the next four years only if they are assured of price modifications in future. The details of the agreement are to be revealed next week and experts believe it will reduce the burden on the federal budget which is still considering the source of funds to pay for its health reform package.
In the case of a cough or a sore throat, the doctor can usually diagnose a common cold immediately. However, the diagnosis of hereditary illnesses like cystic fibrosis, which affects the metabolism, or Huntington's disease, which leads to cognitive decline, is much more complex.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
› Verified 5 days ago
| Entity Name | Sturdy Memorial Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063866176 PECOS PAC ID: 9537152806 Enrollment ID: O20160811001583 |
News Archive
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced the Food and Drug Administration (FDA) has granted final approval for the BIOTRONIK Lumax 740 DX System.
According to an Australian Financial Review report the major pharmaceutical companies have agreed to reduce the Australian government's medicine bill by AUD $2 billion over the next four years only if they are assured of price modifications in future. The details of the agreement are to be revealed next week and experts believe it will reduce the burden on the federal budget which is still considering the source of funds to pay for its health reform package.
In the case of a cough or a sore throat, the doctor can usually diagnose a common cold immediately. However, the diagnosis of hereditary illnesses like cystic fibrosis, which affects the metabolism, or Huntington's disease, which leads to cognitive decline, is much more complex.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Thomas Fabrizio, DO 211 Park St, Attleboro, MA 02703-3143 Ph: (508) 236-8938 | Dr Michael Thomas Fabrizio, DO 8 Pinewood Ln, Cumberland, RI 02864-4225 Ph: (401) 333-2265 |
News Archive
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced the Food and Drug Administration (FDA) has granted final approval for the BIOTRONIK Lumax 740 DX System.
According to an Australian Financial Review report the major pharmaceutical companies have agreed to reduce the Australian government's medicine bill by AUD $2 billion over the next four years only if they are assured of price modifications in future. The details of the agreement are to be revealed next week and experts believe it will reduce the burden on the federal budget which is still considering the source of funds to pay for its health reform package.
In the case of a cough or a sore throat, the doctor can usually diagnose a common cold immediately. However, the diagnosis of hereditary illnesses like cystic fibrosis, which affects the metabolism, or Huntington's disease, which leads to cognitive decline, is much more complex.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019.
› Verified 5 days ago